Our previous studies reported that cancer-derived galectin-1 contributes to DC impairment [14], and that elevated levels of IDO, an important immunosuppression enzyme, are expressed in tolerogenic DCs in the cancer microenvironment [19]. This evidence concerns the gene IDO1 and cancer.